Medical treatment of obesity: The past, the present and the future
Medical treatment of obesity: The past, the present and the future
复制标题
DOI：
10.1016/j.bpg.2014.07.015
复制
发表时间：
2014-08-01
影响因子：
3.2
通讯作者：
Bray, George A.
中科院分区：
文献类型：
--
作者：
Bray, George A.
治疗肥胖症的药物在世纪末和20世纪初开始出现。安非他明成瘾导致寻找没有成瘾特性的类似药物。目前在美国批准的四种拟交感神经药物来自这次搜索，但可能不会在其他地方获得批准。当去甲肾上腺素能药物与去甲肾上腺素能药物联合使用时，可诱导额外的体重减轻。目前，有三种药物（奥利司他、芬特明/托吡酯和氯卡色林）被美国FDA批准用于长期使用，四种拟交感神经药物被美国FDA批准用于短期治疗肥胖。脂肪细胞产生的瘦素和胃肠道激素胰高血糖素样肽-1为肥胖的治疗提供了新的分子基础。已经尝试了作用于大脑中的黑皮质素系统或模拟GLP-1的新类别的药剂，并取得了不同的成功。联合治疗可以大大增加体重减轻;未来有希望的方法。(C)2014爱思唯尔有限公司版权所有。
Medications for the treatment of obesity began to appear in the late 19th and early 20th century. Amphetamine-addiction led to the search for similar drugs without addictive properties. Four sympathomimetic drugs currently approved in the US arose from this search, but may not be approved elsewhere. When noradrenergic drugs were combined with serotonergic drugs, additional weight loss was induced. At present there are three drugs (orlistat, phentermine/topiramate and lorcaserin) approved for long-term use and four sympathomimetic drugs approved by the US FDA for short-term treatment of obesity. Leptin produced in fat cells and glucagon-like peptide-1, a gastrointestinal hormone, provide a new molecular basis for treatment of obesity. New classes of agents acting on the melanocortin system in the brain or mimicking GLP-1 have been tried with variable success. Combination therapy can substantially increase weight loss; a promising approach for the future. (C) 2014 Elsevier Ltd. All rights reserved.